ClinicalTrials.gg
CompletedNCT07936994PROMUSCLE2025Updated Nov 18, 2026

Protein Supplement in Patients With Insufficient Protein Intake and/or Increased Requirements.

An interventional study of HMB-Enriched Protein Module and Suplemento HP/HC in Protein Deficiency and Nutritional Risk, sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jun 2025, registered Sep 2026).
Updated Nov 18, 2026Study documents postedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

ProMuscle2025 is a prospective, randomized, open-label, two-parallel-group, post-marketing clinical trial designed to evaluate the efficacy, tolerability, and safety of an HMB-enriched protein module in adults with insufficient protein intake and/or increased protein requirements. Disease-related malnutrition and sarcopenia are characterized by progressive loss of muscle mass and strength, impaired physical function, and poorer clinical outcomes. Inadequate protein intake is a major contributor to this process. Beta-hydroxy-beta-methylbutyrate (HMB), an active metabolite of leucine, has anabolic and anti-catabolic properties and may support muscle protein synthesis and preservation of lean tissue. However, additional controlled clinical evidence is needed in nutritionally vulnerable patients with heterogeneous chronic conditions.

The study will be conducted in adults aged ≥18 years attending the Endocrinology and Nutrition Department of Hospital Universitario Virgen de la Victoria, Málaga, Spain. Eligible participants must have increased protein requirements and/or nutritional risk with protein needs not adequately covered, be able to perform the planned functional tests, and provide written informed consent. Participants with severe or decompensated comorbidities, allergy to study-product components, current participation in another clinical trial, or ongoing supplementation with HMB-containing products will be excluded.

Participants will be randomly assigned using a computerized system to either an experimental group or a comparator group. Both groups will receive a nutritional and physical-exercise program according to routine clinical practice. In addition, the experimental group will receive the HMB-enriched protein module ProSup Protein® at a dose individualized according to the participant's protein requirements. The comparator group will receive standard nutritional management, ensuring that nutritional requirements are adequately covered. The recruitment period is planned for 6 months, and each participant will be followed for 3 months, with assessments at baseline, a telephone visit at 1.5 months, and a final in-person visit at 3 months.

The main outcomes will assess changes in physical function, muscle composition, and nutritional status. Functional assessment will include handgrip and quadriceps dynamometry, the Timed Up and Go test, sit-to-stand tests, and 20-repetition-maximum performance. Muscle and body-composition assessment will include rectus femoris ultrasound and bioelectrical impedance vector analysis, including body cell mass, phase angle, standardized phase angle, fat-free mass index, appendicular skeletal muscle index, and skeletal muscle index. Disease-related malnutrition and sarcopenia will be evaluated using GLIM and EWGSOP2 criteria, respectively. Secondary outcomes will include adherence to supplementation and product tolerability, including adverse events.

The target recruitment is 118 participants, allowing for an estimated 20% attrition and aiming for 98 evaluable participants (49 per group). Analyses will include intention-to-treat and per-protocol approaches, repeated-measures comparisons, and multivariable models. The study aims to determine whether an HMB-enriched protein module can improve muscle function, body composition, and nutritional status while maintaining good adherence, tolerability, and safety compared with standard nutritional care.

Read the detailed description

Disease-related malnutrition and loss of skeletal muscle are frequent complications of chronic disease and other clinical conditions associated with reduced nutrient intake, increased metabolic requirements, inflammation, or a combination of these factors. Inadequate protein availability may contribute to a negative protein balance, progressive loss of muscle tissue, reduced muscle strength, and impaired physical performance. These changes may occur even when conventional indicators such as body weight or body mass index do not adequately reflect deterioration in nutritional and functional status.

The ProMuscle study is based on a morphofunctional approach to nutritional assessment. This approach integrates information on body composition with measures of muscle function, rather than relying exclusively on anthropometric parameters. The rationale is that changes in muscle quantity, muscle quality, cellular status, and physical performance may provide complementary information regarding the response to nutritional therapy.

Beta-hydroxy-beta-methylbutyrate (HMB) is a bioactive metabolite derived from leucine metabolism. HMB has been investigated for its potential role in the regulation of skeletal muscle protein turnover. Experimental and clinical evidence suggests that HMB may support muscle protein synthesis through anabolic signaling pathways, including pathways related to mammalian target of rapamycin (mTOR), while also reducing pathways involved in muscle protein degradation. These properties provide the biological rationale for evaluating HMB-containing nutritional strategies in individuals who are unable to meet their protein requirements or who have increased protein needs.

The nutritional intervention evaluated in this study consists of a whey-protein module enriched with HMB (ProSup Protein®, Persan Farma S.L.), classified as a food for special medical purposes. The amount administered is individualized according to the estimated protein requirements of each participant rather than using a uniform supplementation dose. This approach is intended to reflect nutritional management in routine clinical practice, where protein supplementation is adjusted according to the patient's nutritional requirements. Participants assigned to the comparison strategy continue to receive nutritional management according to standard clinical practice, with the objective of ensuring adequate nutritional care in both study groups.

An important methodological component of the study is the use of complementary morphofunctional techniques to characterize changes occurring during nutritional intervention. Bioelectrical impedance vector analysis provides information derived from the electrical properties of tissues and allows evaluation of parameters related to body cell mass, hydration, and cellular integrity. In particular, phase angle is considered a potentially useful marker of cellular health and nutritional status that can be monitored independently of conventional body-weight measurements.

Muscle ultrasound provides an additional direct, non-invasive assessment of skeletal muscle morphology. Assessment of the rectus femoris enables changes in muscle dimensions to be investigated over time and complements indirect estimates of muscle mass obtained from bioelectrical impedance. Functional assessment is incorporated because improvements in muscle structure do not necessarily translate directly into improvements in strength or physical performance. The integration of morphological and functional measurements therefore provides a multidimensional characterization of the response to nutritional treatment.

The study also evaluates nutritional status within internationally recognized frameworks for disease-related malnutrition and sarcopenia. This allows changes observed using emerging morphofunctional techniques to be interpreted alongside established clinical diagnostic constructs.

The study was designed to detect clinically relevant differences in muscle-related parameters while accounting for expected losses during follow-up. Statistical analyses will examine changes over time and differences between intervention strategies and will include both intention-to-treat and per-protocol approaches. Multivariable analyses will be used, where appropriate, to explore clinical factors associated with the response to nutritional intervention.

Overall, ProMuscle is intended to provide additional clinical evidence on whether individualized supplementation with an HMB-enriched protein module can enhance the effects of standard nutritional and physical-exercise management in patients with insufficient protein intake or increased protein requirements. The study also seeks to contribute to the clinical application of morphofunctional assessment as a strategy for monitoring the response to nutritional therapy.

02

Conditions studied

  • Protein Deficiency
  • Nutritional Risk

Browse trials for

Keywords

  • Beta-hydroxy-beta-methylbutyrate (HMB)
  • Morphofunctional assessment
  • Disease-related malnutrition
  • Nutritional intervention
  • Bioelectrical impedance analysis
03

In context

Protein Deficiency

21 studies on the registry are indexed under Protein Deficiency; 4 are open to participants now.

This study's enrollment of 120 is above the median of 71 across 18 interventional studies indexed under Protein Deficiency.

Browse Protein Deficiency studies →

Lead sponsor

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud is the lead sponsor of 72 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • Patients with increased protein requirements.
  • Patients meeting criteria for nutritional risk whose protein requirements are not adequately met.
  • Patients able to perform the functional tests included in the study.
  • Patients who provide written .

Exclusion criteria

Exclusion Criteria:

  • Severe or decompensated comorbidities (e.g., class III-IV heart failure, decompensated , or uncontrolled diabetes mellitus).
  • Known allergy to any component of the study protein module.
  • Participation in another clinical trial at the time of enrollment.
  • Current use of nutritional supplements and/or nutritional modules enriched with beta-hydroxy-beta-methylbutyrate (HMB).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Experimental Arm: HMB-Enriched Protein Module

    Arm Description: Participants assigned to the experimental arm will receive an individualized nutritional and physical exercise program according to clinical practice, together with an HMB-enriched whey protein module (ProSup Protein®, Persan Farma S.L.). The amount of protein supplementation will be individualized according to each participant's estimated protein requirements and usual dietary intake. The intervention is intended to supplement protein intake when nutritional requirements are not adequately met through the usual diet.

    Dietary Supplement: HMB-Enriched Protein Module

  • Active comparator
    Comparator Arm - Standard Nutritional Care

    Participants assigned to the comparator arm will receive standard nutritional management and a physical exercise program according to routine clinical practice. Nutritional treatment will be individualized to ensure that each participant's nutritional and protein requirements are adequately covered. Participants in this arm will not receive the HMB-enriched protein module evaluated in the experimental arm. This wording accurately reflects the distinction made in the protocol between a "nutrition and exercise programme + HMB-enriched protein supplement" and a "nutrition and exercise programme based on standard clinical practice".

    Dietary Supplement: Suplemento HP/HC

Interventions

  • Dietary supplementHMB-Enriched Protein Module

    Participants assigned to the experimental arm will receive an individualized nutritional and physical exercise program according to clinical practice, together with an HMB-enriched whey protein module (ProSup Protein®, Persan Farma S.L.). The amount of protein supplementation will be individualized according to each participant's estimated protein requirements and usual dietary intake. The intervention is intended to supplement protein intake when nutritional requirements are not adequately met through the usual diet.

  • Dietary supplementSuplemento HP/HC

    Participants assigned to the comparator arm will receive standard nutritional management and a physical exercise program according to routine clinical practice. Nutritional treatment will be individualized to ensure that each participant's nutritional and protein requirements are adequately covered. Participants in this arm will not receive the HMB-enriched protein module evaluated in the experimental arm.

    Also known as: MERITENE

06

What researchers measure

Primary outcomes

  1. Change in Handgrip Strength

    Handgrip strength will be assessed by dynamometry and recorded in kilograms (kg). Change from baseline will be compared between study groups.

    Time frame: Baseline to 3 months

  2. Change in Phase Angle

    Phase angle will be assessed by bioelectrical impedance analysis and recorded in degrees (°).

    Time frame: Baseline to 3 months

Secondary outcomes

  1. Adherence to the HMB-Enriched Protein Module According to the Wanden-Berghe Questionnaire

    Adherence to nutritional supplementation will be assessed using the Wanden-Berghe adherence questionnaire. The questionnaire evaluates knowledge and difficulties related to nutritional treatment and provides an overall adherence classification.

    Time frame: 1.5 month

  2. Quantitative Adherence to the Prescribed Protein Module

    Adherence will also be evaluated quantitatively by comparing actual intake of the protein module with the prescribed intake, using recall and dispensing records.

    Time frame: 1.5 months and 3 months

07

Study locations

1 site
  • Hospital Universitario Virgen de la Victoria
    Málaga, Málaga 29010, Spain
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available. Study data will be coded and handled in accordance with the General Data Protection Regulation (GDPR) and applicable Spanish data protection legislation, with access restricted to authorized study personnel. The current protocol does not include a prospective mechanism for public sharing of individual-level participant data beyond the purposes authorized for this study. Aggregate study results will be disseminated through scientific communications and publications.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Apr 2026, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Nov 13, 2026
StartActual
Jun 16, 2025
Primary completionActual
Apr 17, 2026
CompletionActual
Jun 17, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Documents
Nov 18, 2026
Registered
First appeared on the registry
Nov 13, 2026
Show all 2 updates
  1. Nov 18, 2026
    + 2 other changes: index terms and conditions
  2. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07936994
Lead sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Jun 16, 2025
Primary completion
Apr 17, 2026
Completion
Jun 17, 2026
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion